PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.

ABSTRACT:

Background

Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity of the tumors hampers the success of therapies targeting the MAPK/ERK pathway alone. Dissecting this heterogeneity will contribute to identifying key players in the oncogenic progression to tailor more effective therapies.

Methods

We performed a comprehensive molecular and phenotypic characterization of a panel of patient-derived BRAF^V600E-positive melanoma cell lines. Transcriptional profiling was used to identify groups of coregulated genes whose expression relates to an increased migratory potential and a higher resistance.

Results

A decrease in sensitivity to MAPK/ERK pathway inhibition with vemurafenib o

SUBMITTER: Corrales E 

PROVIDER: S-EPMC9700886 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature